Effects of Creatine Formulations on Exercise and Cognitive Performance
Effects of Creatine Monohydrate Versus a Multi-Ingredient Creatine Formulation on Exercise Performance, Cognitive Function, Hydration, and Gastrointestinal Tolerability
This study will examine whether a multi-ingredient creatine supplement produces different effects on exercise performance, cognitive function, hydration, and gastrointestinal symptoms compared with creatine monohydrate alone.
Approximately 16 healthy, physically active adults aged 18-40 years will participate. Each participant will take creatine monohydrate (5 grams per day) for 18 days and a multi-ingredient supplement containing creatine monohydrate (5 grams), sodium, potassium, magnesium, and taurine for another 18 days. The order of supplementation will be randomly assigned, with a 30-day break between conditions.
Participants will complete laboratory testing before and after each supplementation period. Testing will include bench press exercise to assess muscular endurance, repeated high-intensity cycling tests to assess exercise performance, and a computerized cognitive task to measure attention and reaction time. Researchers will also assess hydration, selected blood markers, perceived exertion, and gastrointestinal symptoms.
The findings may help determine whether adding electrolytes and taurine to creatine provides additional benefits or produces different physiological responses compared with creatine monohydrate alone.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Terence A Moriarty
- Phone Number: 319-273-6866
- Email: terence.moriarty@uni.edu
Study Locations
-
-
Iowa
-
Cedar Falls, Iowa, United States, 50614
- Recruiting
- Wellness and Recreation Center
-
Contact:
- Terence A Moriarty
- Phone Number: 319-273-6866
- Email: terence.moriarty@uni.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18-40 years.
- Apparently healthy individuals who are physically active and capable of performing vigorous exercise.
- Willing and able to complete repeated maximal-intensity cycling tests, bench press exercise, and cognitive assessments.
- Willing to consume both assigned dietary supplement formulations for 18 days each, separated by a 30-day washout period.
- Willing to refrain from taking additional creatine or electrolyte supplements during the study, including the washout period.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- History of cardiovascular, metabolic, renal, neurological, or musculoskeletal conditions that may contraindicate vigorous exercise or interfere with study outcomes.
- Current injury or physical limitation that would prevent safe completion of the exercise testing procedures.
- Current pregnancy or plans to become pregnant during the study.
- Recent creatine supplementation prior to enrollment.
- Current use of medications or dietary supplements that may interfere with creatine metabolism, hydration status, exercise performance, cognitive function, or participant safety.
- Known allergy, intolerance, or contraindication to any ingredient in the study supplements.
- Unwillingness or inability to comply with supplementation, washout, or laboratory testing requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Creatine Monohydrate Followed by Multi-Ingredient Creatine
Participants will receive creatine monohydrate (5 g/day) with sugar-free flavoring for 18 consecutive days, followed by a 30-day washout period. Participants will then receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period. |
Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. |
|
Experimental: Multi-Ingredient Creatine Followed by Creatine Monohydrate
Participants will receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for 18 consecutive days, followed by a 30-day washout period. Participants will then receive creatine monohydrate (5 g/day) with sugar-free flavoring for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period. |
Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Bench Press Repetitions
Time Frame: Baseline and Day 18 of each supplementation period.
|
Total number of repetitions completed across three sets of bench press exercise at 70% of baseline one-repetition maximum (1RM), performed to volitional fatigue with one minute of rest between sets. |
Baseline and Day 18 of each supplementation period.
|
|
Peak Power During Repeated Wingate Tests
Time Frame: Baseline and Day 18 of each supplementation period.
|
Peak power output (watts) measured during three consecutive 30-second Wingate cycling tests, performed with standardized recovery periods. |
Baseline and Day 18 of each supplementation period.
|
|
Mean Power During Repeated Wingate Tests
Time Frame: Baseline and Day 18 of each supplementation period.
|
Mean power output (watts) measured during each of three 30-second maximal-effort Wingate cycling tests. |
Baseline and Day 18 of each supplementation period.
|
|
Total Work During Repeated Wingate Tests
Time Frame: Baseline and Day 18 of each supplementation period.
|
Total mechanical work (kilojoules) completed across three 30-second Wingate cycling tests. |
Baseline and Day 18 of each supplementation period.
|
|
Stroop Interference Reaction Time
Time Frame: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
Cognitive performance assessed using a computerized Stroop task completed before exercise and during recovery between repeated Wingate tests. Reaction time (milliseconds) will be used to evaluate changes in cognitive performance as exercise-induced fatigue accumulates. |
Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
|
Stroop Task Accuracy
Time Frame: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
Percentage of correct responses during a computerized Stroop task administered before exercise and during recovery between repeated Wingate cycling tests. |
Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wingate Fatigue Index
Time Frame: Baseline and Day 18 of each supplementation period.
|
Percentage decline in power output during repeated Wingate tests. |
Baseline and Day 18 of each supplementation period.
|
|
Rating of Perceived Exertion
Time Frame: Baseline and Day 18 of each supplementation period.
|
Perceived exertion assessed using the Borg 6-20 scale following each Wingate. |
Baseline and Day 18 of each supplementation period.
|
|
Blood Lactate Concentration
Time Frame: Baseline and Day 18 of each supplementation period.
|
Blood lactate concentration (mmol/L) measured following each Wingate. |
Baseline and Day 18 of each supplementation period.
|
|
Urine Specific Gravity
Time Frame: Baseline and Day 18 of each supplementation period.
|
Urine specific gravity assessed before and after exercise to evaluate hydration status. |
Baseline and Day 18 of each supplementation period.
|
|
Blood Sodium Concentration
Time Frame: Baseline and Day 18 of each supplementation period.
|
Sodium concentration measured using an i-STAT analyzer. |
Baseline and Day 18 of each supplementation period.
|
|
Blood Potassium Concentration
Time Frame: Baseline and Day 18 of each supplementation period.
|
Potassium concentration measured using an i-STAT analyzer. |
Baseline and Day 18 of each supplementation period.
|
|
Gastrointestinal Symptom Severity
Time Frame: Baseline and Day 18 of each supplementation period.
|
Daily 0-10 ratings of bloating, abdominal discomfort, nausea, diarrhea, constipation, reflux, and overall gastrointestinal discomfort. |
Baseline and Day 18 of each supplementation period.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-FY27-58
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.